Privia Health Group, Inc. (NASDAQ:PRVA) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. trimmed its holdings in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 5.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,077,948 shares of the company's stock after selling 174,389 shares during the quarter. Principal Financial Group Inc. owned approximately 2.56% of Privia Health Group worth $60,175,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of PRVA. Riverbridge Partners LLC increased its holdings in shares of Privia Health Group by 19.7% in the 4th quarter. Riverbridge Partners LLC now owns 5,824,458 shares of the company's stock valued at $113,868,000 after acquiring an additional 958,418 shares during the period. Eventide Asset Management LLC grew its stake in Privia Health Group by 979.2% in the third quarter. Eventide Asset Management LLC now owns 822,438 shares of the company's stock valued at $14,977,000 after purchasing an additional 746,231 shares during the last quarter. Icon Wealth Advisors LLC raised its holdings in Privia Health Group by 1,910.1% in the third quarter. Icon Wealth Advisors LLC now owns 300,889 shares of the company's stock worth $5,479,000 after purchasing an additional 285,920 shares in the last quarter. FMR LLC lifted its position in shares of Privia Health Group by 1.5% during the third quarter. FMR LLC now owns 18,169,043 shares of the company's stock valued at $330,858,000 after buying an additional 271,645 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Privia Health Group by 240.3% during the third quarter. Barclays PLC now owns 224,018 shares of the company's stock valued at $4,079,000 after buying an additional 158,188 shares during the last quarter. Institutional investors own 94.48% of the company's stock.

Wall Street Analysts Forecast Growth

PRVA has been the subject of several recent analyst reports. Stephens reiterated an "overweight" rating and set a $26.00 price objective on shares of Privia Health Group in a research note on Thursday, January 2nd. JMP Securities reaffirmed a "market outperform" rating and set a $26.00 price target on shares of Privia Health Group in a research report on Friday, February 14th. JPMorgan Chase & Co. raised their price objective on Privia Health Group from $27.00 to $28.00 and gave the stock an "overweight" rating in a research report on Friday, November 29th. Barclays upped their target price on Privia Health Group from $19.00 to $21.00 and gave the company an "equal weight" rating in a research report on Friday, November 8th. Finally, Truist Financial raised their price target on Privia Health Group from $24.00 to $27.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Two research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $24.94.

Privia Health Group Stock Performance

Shares of NASDAQ:PRVA traded down $0.11 during trading on Friday, reaching $24.54. The stock had a trading volume of 270,644 shares, compared to its average volume of 585,989. The business has a fifty day moving average price of $21.92 and a 200-day moving average price of $20.36. Privia Health Group, Inc. has a 1-year low of $15.92 and a 1-year high of $25.67. The stock has a market cap of $2.94 billion, a PE ratio of 245.37, a PEG ratio of 3.59 and a beta of 0.87.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.